Ligand Pharmaceuticals (LGND) Operating Income (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Operating Income of $17.4 million for Q1 2026, up 25.46% sequentially from $13.8 million in Q4 2025, and up 147.96% YoY from $7.0 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Operating Income (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Operating Income for 17 years, with the latest figure at $17.4 million in Q1 2026.
- Quarterly Operating Income rose 147.96% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.6 million (up 253.03% YoY) and the FY2025 annual result came in at $41.0 million, up 281.38% from the prior year.
- Operating Income climbed to $17.4 million in Q1 2026 per LGND's latest filing, from $13.8 million in the prior quarter.
- Over five years, Operating Income peaked at $54.9 million in Q3 2025 and troughed at -$36.2 million in Q1 2025.
- A 5-year average of $3.0 million and a median of $3.1 million in 2023 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 1647.73% in 2025, down 1312.05% in 2025.
- Over 5 years, Operating Income stood at -$20.1 million in 2022, then soared by 83.29% to -$3.4 million in 2023, then plunged by 186.99% to -$9.6 million in 2024, then jumped by 243.64% to $13.8 million in 2025, then advanced by 25.46% to $17.4 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $17.4 million, $13.8 million, and $54.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.59 Mn |
| Mar 31, 2026 | 17.37 Mn |
| Dec 31, 2025 | 13.84 Mn |
| Sep 30, 2025 | 54.93 Mn |
| Jun 30, 2025 | 8.44 Mn |
| Mar 31, 2025 | -36.22 Mn |
| Dec 31, 2024 | -9.64 Mn |
| Sep 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | -19.10 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | -3.36 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | -1.98 Mn |
| Mar 31, 2023 | 14.21 Mn |
| Dec 31, 2022 | -20.10 Mn |
| Sep 30, 2022 | 12.34 Mn |
| Jun 30, 2022 | 8.66 Mn |
| Mar 31, 2022 | 2.13 Mn |
| Dec 31, 2021 | 37.69 Mn |
| Sep 30, 2021 | 15.71 Mn |